TP53 mutation analyses on breast carcinomas: A study of paraffin-embedded archival material

British Journal of Cancer

Volumn 74, Issue 4, 1996, Pages 555-561

  Gretarsdottir, S ^a   Tryggvadottir, L ^b   Jonasson, J G ^c   Sigurdsson, H ^c   Olafsdottir, K ^c   Agnarsson, B A ^c   Ogmundsdottir H ^a   Eyfjord J E ^a  

^a ICELANDIC CANCER SOCIETY   (Iceland)

^b ICELANDIC CANCER REGISTRY   (Iceland)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Breast cancer; Constant denaturant gel electrophoresis; Immunohistochemistry; Paraffin embedded archival tissue; Prognosis; TP53 mutation analysis

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL NUCLEUS; CONTROLLED STUDY; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA DETERMINATION; DNA SEQUENCE; EXON; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0029757392     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.400     Document Type: Article

References (40)

1. ANDERSEN TI, HOLM R, NESLAND JM, HEIMDAL KR, OTTESTAD L AND BØRRESEN A-L. (1993). Prognostic significance of TP53 alterations in breast carcinoma. Br. J. Cancer, 68, 540-548.
2. BARNES DM, DUBLIN EA, FISHER CJ, LEVISON DA AND MILLIS RR. (1993). Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum. Pathol., 24, 469-476.
3. BARR L AND BAUM M. (1992). Time to abandon TNM staging of breast cancer. Lancet, 339, 915-917.
4. BERGH J, NORBERG T, SJÖGREN S, LINDGREN A AND HOLMBERG L. (1995). Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med., 1, 1029-1034.
5. BORG Å, LENNERSTRAND J, STENMARK-ASKMALM M, FERNÖ M, BRISFORS A, ÖHRVIK A, STÅL O, KILLANDER D, LANE D AND BRUNDELL J. (1995). Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steriod receptor cytosols. Br. J. Cancer, 71, 1013-1017,
6. BØRRESEN A-L, HOVIG E, SMITH-SØRENSEN B, MALKIN D, LYSTAD S, ANDERSEN TI, NESLAND JM, ISSELBACHER KJ AND FRIEND SH. (1991). Constant denaturant gel electrophoresis as rapid screening technique for p53 mutations. Proc. Natl Acad. Sci. USA, 88, 8405-8409.
7. BØRRESEN A-L, ANDERSEN TI, EYFJÖRD JE, CORNELIS RS, THORLACIUS S, BORG Å, JOHANSSON U, THEILLET C, SCHERNECK S, HARTMAN S, CORNELISSE CJ, HOVIG E AND DEVILEE P. (1995). TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes, Chrom. Cancer, 4, 71-75.
8. CHOU Q, RUSSEL M, BIRCH DE, RAYMOND J AND BLOCH W. (1992). Prevention of pre-PCR mis-priming and primer dimerization improve low-copy number amplifications. Nucleic Acids Res., 20, 1717.
9. CLARKE AR, MAANDAG AR, ROON MV, VAN DER LUGT NMT, VAN DER VALIK M, HOOPER MI, BERNS A AND RIELE HT. (1993). Requirement of a functional RB-1 gene in murine development. Nature, 362, 849-852.
10. COX DR. (1972). Regression models and life tables. J. R. Stat. Soc. B., 34, 187-220.
11. CUNNINGHAM JM, INGLE JN, JUNG SH, CHA SS, WOLD LE, FARR G, WITZIG TE, KROOK JE, WIEAND HS AND KOVACH JS. (1994). p53 gene expression in node-positive breast cancer: relationship to DNA ploidy and prognosis. J. Natl Cancer Inst. 86, 1871-1873.
12. EL-DEIRY WS, TOKINO T, VELCULESCU VE, LEVY DB, PARSON R, TRENT JM, LIN D, MERCER WE, KINZLER KM AND VOGELSTEIN B. (1993). WAF1, a potential mediator of p53 tumour suppression. Cell, 75, 817-825.
13. 1 arrest and apoptosis. Cancer Res., 54, 1169-1174.
14. ELLEDGE RM, FUQUA SAW, CLARK GM, PUJOL P AND ALLRED DC. (1993). The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res. Treat., 27, 95-102.
15. EYFJÖRD JE, THORLACIUS S, STEINARSDOTTIR M, VALGARDSDOTTIR R, ÖGMUNDSDOTTIR HM AND ANAMTHAWAT-JONSSON K. (1995). p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res., 55, 645-651.
16. FISHER CJ, GILLETT CE, VOJTESEK B, BARNES DM AND MILLIS RR. (1994). Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br. J. Cancer, 69, 26-31.
17. GREENBLATT MS, BENNETT WP, HOLLSTEIN M AND HARRIS CC. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878.
18. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B AND HARRIS CC. (1991). p53 mutations in human cancers. Science, 253, 49-53.
19. KASTAN MB, ZHAN Q, EL-DEIRY WS, CARRIER F, JACKS T, WALSH WV, PLUNKETT BS, VOGELSTEIN B AND FORNACE JR AJ. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in Ataxia-Telangiectasia. Cell, 71, 587-597.
20. KERR JF, WINTERFORD CM AND HARMON BV. (1994). Apoptosis its significance in cancer and cancer therapy. Cancer, 73, 2013-2026.
21. LANE DP. (1992). p53, guardian of the genome. Nature, 358, 15-16.
22. LANE DP AND CRAWFORD LV. (1979). T-antigen is bound to a host protein in SV40-transformed cells. Nature, 278, 261-263.
23. LIPPONEN P, JI H, AALTOMA S, SYRJÄNEN S AND SYRJÄNEN K. (1993). p53 protein expression in breast cancer is related to histopathological characteristics and prognosis. Int. J. Cancer, 55, 51-56.
24. LIVINGSTONE LR, WHITE A, SPROUSE J, LIVANOS E, JACKS T AND TLSTY TD. (1992). Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70, 923-935.
25. LOWE SW, SCHMITT EM, SMITH SW, OSBORNE BA AND JACKS T. (1993). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 362, 847-852.
26. LOWE SW, BODIS S, MCCLATCHEY A, REMINGTON L, RULEY HE, FISHER D, HOUSMAN DE AND JACKS T. (1994). p53 status and the efficacy of cancer therapy in vivo. Science, 266, 807-810.
27. MACGROGAN G, BONICHON F, DE MASCAREL I, TROJANI M, DURAND M, AVRIL A AND COINDRE J-M. (1995). Prognastic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res. Treat., 36, 71-81.
28. MCMANUS DT, YAP EPH, MAXWELL P, RUSSELL SEH, TONER PG AND MCGEE JOD. (1994). p53 expression, mutation, and allelic deletion in ovarian cancer. J. Pathol., 174, 159-168.
29. MOMAND J, ZAMBETTI GP, OLSON DC, GEORGE D AND LEVINE AJ. (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell, 69, 1237-1245.
30. NIWA K, ITOH M, MURASE T, MORISHITA N, ITOH N, MORI H AND TAMAYA T. (1994). Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br. J. Cancer, 70, 1191-1197.
31. SAITOH S, CUNNINGHAM J, DE VRIES EMG, MCGOVERN RM, SCHROEDER JJ, HARTMANN A, BLASZYK H, WOLD LE DS, SOMMER SS AND KOVACH JS. (1994). p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene, 9.
32. SMITH ML, CHEN I-T, ZHAN Q, BAE I, CHEN C-Y, GILMER TM, KASTAN MB, M OCP AND FORNACE JAJ. (1994). Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science, 266, 1376-1380.
33. SMITH-SORENSEN B, GEBHARDT MC, KLOEN P, AGUILAR F, FRIEND SH AND BØRRESEN A-L. (1993). Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Hum. Mutat., 2, 274-285.
34. THORLACIUS S, THORGILSSON B, BJÖRNSSON J, TRYGGVADÓTTIR L, BØRRESEN A-L, ÖGMUNDSDÓTTIR HM AND EYFJÖRD JE. (1995). TP53 mutations and abnormal p53 expression protein in breast carcinomas related to prognosis. Eur. J. Cancer, 31A, 1856-1861.
35. WANG J-L, ZHANG Z-J, HARTMAN M, SMITS A, WESTERMARK B, MUHR C AND NISTÉR M. (1995). Detection of TP53 gene mutation in human meningiomas: a study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DNA sequencing techniques on paraffin-embedded samples. Int. J. Cancer, 64, 223-228.
36. WANG XW, YEH H, SCHAEFFER L, ROY R, MONCOLLIN V, EGLY J-M, WANG Z, FRIEDBERG EC, EVANS MK, TAFFE BG, BOHR VA, WEEDA G, HOEIJMAKERS JHJ, FORRESTER K AND HARRIS CC. (1995). p53 associated modulation of TFIIH-associated nucleotide excision repair activity. Nature Genet., 10, 188-195.
37. WANG ZW, FORRESTER K, YEH H, FEITELSON MA, GU J-R AND HARRIS CC. (1994). Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl Acad. Sci. USA, 91, 2230-2234.
38. WRIGHT DK AND MANOS MM. (1990). Sample preparation from paraffin-embedded tissues. In PCR Protocols - A guide to Methods and Applications. Innis MA, Gelfand DH, Sninsky JJ and White TJ (eds) pp. 153-158. Academic Press: San Diego, CA, USA.
39. YIN Y, TAINSKY MA, BISCHOFF FZ, STRONG LC AND WAHL GM. (1992). Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70, 937-948.
40. ZHAN Q, BAE I, KASTAN MB AND J FJA. (1994). The p53-dependent γ-ray response of GADD45. Cancer, 54, 2755-2760.